ArticleBMC ophthalmology2026
Selective laser trabeculoplasty is effective in controlling steroid-induced OHT after 0.19 µg Fluocinolone acetonide implant, a long-term outcome of 15 eyes.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the long-term effectiveness and safety of selective laser trabeculoplasty (SLT) for controlling intraocular pressure (IOP) in patients with steroid-induced ocular hypertension (OHT) treated with fluocinolone acetonide (FAc) intravitreal implants.
methodsThis was a single-center retrospective case series of patients with steroid-induced OHT. Eligibility required prior to exposure to ≥ 3 sustained-release dexamethasone intravitreal implants per eye. SLT was performed in all eyes either before (group 1, n = 6), after (group 2, n = 6), or both before and after (group 3, n = 3) the FAc implantation. IOP was analysed with linear mixed-effects models (random intercept for eye). The mean IOP and within-eye variability (SD-IOP) were summarized for the pre-SLT and post-SLT periods.
resultsFifteen eyes from thirteen patients treated for macular edema were followed for 32 ± 17.7 months after SLT. The mean IOP decreased by 14.2 mmHg across the cohort (p < 0,001). In group 1, which was treated with SLT before FAc implantation, the mean IOP decreased from 16.5 ± 4.8 mmHg to 13.7 ± 2.1 mmHg (p < 0.001) with significantly reduced IOP variability (-2.1 mmHg, p < 0.001). No eye required filtering surgery. Steroid-induced OHT resolved in all eyes within ≤ 4 months after the last dexamethasone implant and ≤ 36 months after the FAc implant.
conclusionSLT is a safe, effective, and repeatable intervention for preventing or controlling IOP elevation in OHT responders' eyes receiving FAc implants. Performing SLT prior to FAc injection may offer better IOP control and reduce variability in such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.